INTRODUCTION: Pyoderma gangrenosum (PG) is an idiopathic, non–infectious ulcerating disorder predominantly involving skin, with primarily neutrophilic inflammatory infiltrate. The mainstay of therapy for PG has been high–dose corticosteroids but systemic agents such as cyclophosphamide, cyclosporine or azathioprine can be used. AIMS: To evaluate efficacy and safety of oral cyclosporine in patients with pyoderma gangrenosum. MATERIALS AND METHOD: A retrospective study of patients presenting with pyoderma gangrenosum from February 2014 to February 2018 was carried out. All patients were given oral cyclosporine 3 mg/kg/day for minimum 6 weeks to maximum 12 weeks as per requirement. At the end of therapy patients were classified according to response and reduction ulcer area score. RESULTS: Ulcer area in each patient reduced above 60% with minimal side effects after giving cyclosporine for 12 weeks. Out of 27 patients, 12 had excellent response (>90%). While 10 patients had good response (70–90 %) and 5 had good response (50–70%). CONCLUSION: This study shows that systemic low dose cyclosporine is an effective and safe treatment option available for pyoderma gangrenosum.